These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 17099832)

  • 1. Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children.
    Porowski T; Zoch-Zwierz W; Wasilewska A; Spotyk A; Konstantynowicz J
    Pediatr Nephrol; 2007 Apr; 22(4):514-20. PubMed ID: 17216257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas.
    Laube N; Hergarten S; Hoppe B; Schmidt M; Hesse A
    J Urol; 2004 Jul; 172(1):355-9. PubMed ID: 15201810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls?
    Kavanagh JP; Laube N
    J Urol; 2006 Feb; 175(2):766-70. PubMed ID: 16407047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bonn Risk Index based micromethod for assessing risk of urinary calcium oxalate stone formation.
    Porowski T; Mrozek P; Sidun J; Zoch-Zwierz W; Konstantynowicz J; Kirejczyk JK; Motkowski R; Laube N
    J Urol; 2010 Mar; 183(3):1157-62. PubMed ID: 20096860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of the treatment of calcium-oxalate stone formers with the Bonn-Risk-Index].
    Laube N; Schmidt M; Hesse A
    Urologe A; 2003 Feb; 42(2):243-9. PubMed ID: 12607094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The alteration of urine composition due to stone material present in the urinary tract.
    Laube N; Pullmann M; Hergarten S; Schmidt M; Hesse A
    Eur Urol; 2003 Nov; 44(5):595-9. PubMed ID: 14572760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extended metabolic diagnosis of urolithiasis].
    Laube N; Bradenahl J; Thomas E; Meissner A; Müller SC
    Aktuelle Urol; 2006 Nov; 37(6):436-42; quiz 423-4. PubMed ID: 17099832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New diagnostic tool for individual monitoring of urolithiasis risk and other metabolic diseases].
    Laube N; Klein F; Bernsmann F; Fisang C
    Dtsch Med Wochenschr; 2014 Aug; 139(34-35):1721-5. PubMed ID: 25116022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of stone disease.
    Porena M; Guiggi P; Micheli C
    Urol Int; 2007; 79 Suppl 1():37-46. PubMed ID: 17726351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluid intake and epidemiology of urolithiasis.
    Siener R; Hesse A
    Eur J Clin Nutr; 2003 Dec; 57 Suppl 2():S47-51. PubMed ID: 14681713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of calcium oxalate urolithiasis.
    Gerstenbluth RE; Resnick MI
    Med Clin North Am; 2004 Mar; 88(2):431-42. PubMed ID: 15049586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metaphylaxis of urolithiasis.
    Menditto VG; Milanese G; Muzzonigro G
    Arch Ital Urol Androl; 2009 Mar; 81(1):32-9. PubMed ID: 19499756
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.